Antibody conjugate radioimmunotherapy of superficial bladder cancer
Braz. arch. biol. technol
; 45(spe): 87-89, Sept. 2002. ilus
Article
em En
| LILACS
| ID: lil-329811
Biblioteca responsável:
BR1.1
ABSTRACT
The administration of antibody conjugates for cancer therapy is now proving to be of clinical value. We are currently undertaking a programme of clinical studies using the monoclonal antibody C595 (IgG3) which reacts with the MUC1 glycoprotein antigen that is aberrantly expressed in a high proportion of bladder tumours. Radioimmunoconjugates of the C595 antibody have been produced with high radiolabelling efficiency and immunoreactivity using Tc-99m and In-111 for diagnostic imaging, and disease staging and the cytotoxic radionuclides Cu-67 and Re-188 for therapy of superficial bladder cancer. A Phase I/II therapeutic trail involving the intravesical administration of antibody directly into the bladder has now begun
Texto completo:
1
Índice:
LILACS
Idioma:
En
Revista:
Braz. arch. biol. technol
Assunto da revista:
BIOLOGIA
Ano de publicação:
2002
Tipo de documento:
Article